What is acinic cell carcinoma?
Acinic cell carcinoma (AciCC) is a slow-growing cancer of the salivary glands. In the large majority of people it starts in the parotid gland, the salivary gland in front of the ear. Less often it arises in the submandibular gland, the small salivary glands of the mouth, or, rarely, elsewhere in the head and neck.
The tumour gets its name from the acinar cells it resembles. These are the cells at the ends of the salivary gland ducts that make saliva, and they are packed with small enzyme-containing granules.
AciCC is usually a low-grade cancer. It tends to grow over months or years and is often cured by surgery. However, it can come back many years later, and a small number of tumours change into a more aggressive form, called high-grade transformation.
AciCC can occur at any age, including in children and teenagers, and is slightly more common in women. In 2019 researchers discovered that most AciCCs are driven by a chromosome rearrangement that switches on a gene called NR4A3; staining for this protein is now a reliable diagnostic test (Haller et al., 2019).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Usually low-grade salivary gland carcinoma |
| How common | Uncommon; one of the more frequent salivary cancers, making up several per cent of them |
| Typical age | Any age; most often 40-60; also one of the commonest salivary cancers in children |
| Sex | Slightly more common in women (about 6 in 10 cases) |
| Main site | Parotid gland in most; also submandibular and minor salivary glands |
| Key gene change | Rearrangement that activates NR4A3 (or, less often, NR4A2) |
| Main treatment | Surgical removal (parotidectomy) |
| Outlook | Very good; disease-specific survival around 94% at 10 years |
| Special feature | Late recurrences can occur, so long-term follow-up is advised |
2. Causes and risk factors
The cause of acinic cell carcinoma is not known. It is not clearly linked to smoking, alcohol or viruses.
| Risk factor | Notes |
|---|---|
| Previous radiation to the head and neck | A recognised risk factor for salivary gland cancers in general |
| Female sex | Women are affected slightly more often |
| Family history | Very rare reports; not considered inherited |
Gene changes
| Gene change | Notes |
|---|---|
| NR4A3 activation | Caused by a chromosome swap that places a strong “on switch” (enhancer) next to NR4A3; found in most tumours |
| NR4A2 rearrangement | Found in a minority of tumours without NR4A3 changes |
| Other fusions | Rare partner genes have been described (Zhu et al., 2024) |
These changes occur only in the tumour cells. They are not inherited.
A tumour that used to be confused with AciCC
Some tumours once called acinic cell carcinoma are now known to be a separate cancer, secretory carcinoma, which carries an ETV6::NTRK3 fusion. Telling them apart matters because secretory carcinoma can respond to NTRK-blocking drugs. NR4A3 staining helps make this distinction (Wong, Mariño-Enriquez and Hornick, 2021).
3. How does it look
To the patient
AciCC usually appears as a slowly enlarging, painless lump in front of the ear or at the angle of the jaw.
| Feature | Description |
|---|---|
| Feel | Firm or rubbery, usually mobile |
| Size | Often 1-3 cm when found |
| Growth | Slow, sometimes present for years |
| Skin | Normal in most cases |
| Pain | Uncommon; may occur in up to a third |
On scans
On ultrasound or MRI, AciCC usually appears as a well-defined mass, sometimes with cystic areas. It may look very similar to a benign tumour, such as a pleomorphic adenoma or Warthin tumour, which is why tissue diagnosis is essential.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Large polygonal cells with blue, grainy (zymogen-rich) cytoplasm |
| Patterns | Solid, microcystic, papillary-cystic and follicular |
| Lymphoid tissue | A dense background of lymphocytes in some tumours |
| Special stains | PAS-positive granules resistant to diastase; DOG1 and SOX10 positive |
| Diagnostic marker | Nuclear NR4A3 staining, highly specific for AciCC (Haller et al., 2019b) |
| High-grade change | Areas of very abnormal cells, necrosis and many mitoses |
Acinic cell carcinoma in children and young people
Salivary gland cancers are rare in children, but when they occur, acinic cell carcinoma is among the commonest types, second only to mucoepidermoid carcinoma. In young people it usually appears as a painless parotid lump and is most often low grade.
Treatment follows the same principles as in adults, with careful surgery that preserves the facial nerve. Radiotherapy is used sparingly in children because of its effects on growth of the face and jaw and the small risk of later second cancers. The outlook for children is generally excellent.
High-grade transformation
In a small number of people, part of an AciCC changes into a much more aggressive, high-grade cancer. This is sometimes called dedifferentiation. These tumours:
- often grow quickly and may cause pain or facial weakness
- are more likely to spread to lymph nodes and distant organs
- usually need wider surgery, neck dissection and radiotherapy
- have a less favourable outlook than typical AciCC
4. Symptoms
Common symptoms
- A painless lump in front of or below the ear
- A lump under the jaw or inside the mouth, depending on the gland involved
- Slow growth over months or years
- Mild pain or tenderness in some people
Warning signs of more aggressive disease
| Sign | What it may mean |
|---|---|
| Facial weakness or drooping | Involvement of the facial nerve |
| Rapid growth | Possible high-grade transformation |
| Fixed, hard lump | Spread into surrounding tissue |
| Lumps in the neck | Spread to lymph nodes |
| Numbness of the face or ear | Nerve involvement |
Symptoms of spread
| Site | Possible symptoms |
|---|---|
| Lymph nodes | Swelling in the neck |
| Lungs | Cough or breathlessness |
| Bone | Bone pain |
When to seek medical advice
See a doctor about any lump in the face, jaw or neck lasting more than 3 weeks. Seek prompt review if it is growing, painful, fixed or linked with facial weakness. In children, any persistent lump in the parotid area should be checked.
5. Diagnosis
| Test | Purpose |
|---|---|
| Head and neck examination | Assesses the lump, nodes and facial nerve |
| Ultrasound | First test; guides needle sampling |
| Fine needle aspiration (FNA) | Samples cells; may be difficult to interpret |
| Core needle biopsy | Provides more tissue if needed |
| MRI | Shows the extent of the tumour and its relation to the facial nerve |
| CT or PET-CT | For high-grade tumours or suspected spread |
| NR4A3 staining | Confirms AciCC and excludes mimics (Meiklejohn et al., 2023) |
Staging
Like other salivary gland cancers, AciCC is staged with the TNM system, which records the size and local extent of the tumour (T), any lymph node spread (N) and any distant spread (M). Most AciCCs are found at an early stage (I or II), when the tumour is confined to the gland.
6. Treatment
Treatment is planned by a head and neck cancer team.
Surgery
| Operation | Notes |
|---|---|
| Superficial parotidectomy | Removes the outer part of the parotid; enough for many small tumours |
| Total parotidectomy | For deeper or larger tumours |
| Facial nerve preservation | The nerve is kept whenever it is not invaded |
| Submandibular gland excision | For tumours in that gland |
| Neck dissection | When nodes are involved or the tumour is high grade or large |
Radiotherapy
Radiotherapy after surgery is not needed for most people with small, completely removed, low-grade tumours. It may be advised for:
- Close or positive margins
- High-grade or transformed tumours
- Large tumours or spread outside the gland
- Lymph node involvement
- Nerve invasion or recurrent disease
Treatment for advanced disease
| Option | Notes |
|---|---|
| Further surgery | For local or nodal recurrence when possible |
| Radiotherapy | For local control or symptom relief |
| Chemotherapy | Limited benefit; used for widespread disease |
| Targeted drugs | Based on tumour profiling, or within trials |
Side effects
| Treatment | Possible side effects |
|---|---|
| Parotid surgery | Temporary facial weakness, numb ear lobe, gustatory sweating (Frey syndrome), change in face shape |
| Neck dissection | Shoulder stiffness, numbness, scarring |
| Radiotherapy | Dry mouth, sore skin, taste changes, jaw stiffness, dental problems |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Parotidectomy | General anaesthetic; usually 1-2 nights in hospital |
| Drain and stitches | Drain removed after 1-2 days; stitches after about a week |
| Recovery | Most people return to normal activities within 2-3 weeks |
| Radiotherapy, if needed | Weekday sessions for about 6 weeks |
7. Outlook (prognosis)
| Measure | Approximate figures |
|---|---|
| Disease-specific survival at 5 years | About 97% |
| At 10 years | About 94% |
| At 20 years | About 90% |
| With distant spread | Much lower; about 22% at 20 years |
These figures come from more than 1,100 people in the US SEER registry (Patel et al., 2014). A larger SEER analysis of over 2,600 head and neck cases found similar results and showed that high grade, advanced stage and male sex were linked with a worse outlook, while surgery was linked with better survival (Yibulayin et al., 2020).
Because these tumours grow slowly, recurrence can appear 10 years or more after surgery, and some people live for many years even after the cancer has come back. Small, low-grade tumours removed with clear margins carry the lowest risk.
Factors linked with a poorer outlook
- High-grade transformation
- Large tumour or spread beyond the gland
- Facial nerve involvement
- Lymph node or distant spread
- Incomplete removal
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic visits every 3-6 months at first | Examine the parotid area, neck and facial nerve |
| Ultrasound or MRI | Detect recurrence |
| Chest imaging | For higher-risk tumours |
| Long-term follow-up for 10 years or more | Recurrences can appear many years after surgery |
9. Living with acinic cell carcinoma
- Check the scar and the area around it for new lumps
- Keep up long-term follow-up, even if you feel well
- Massage the scar once healed, if advised, to soften it
- Use antiperspirant or ask about treatment if Frey syndrome causes sweating when eating
- Look after your teeth and mouth, especially after radiotherapy
- Report any facial weakness, new pain or a lump in the neck without waiting for your next appointment
- Seek support from head and neck cancer charities and patient groups
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is acinic cell carcinoma a real cancer? | Yes, but it is usually low grade and very treatable |
| Can children get it? | Yes; it is one of the more common salivary cancers in young people |
| Is it inherited? | No |
| Will I need chemotherapy? | Rarely |
| Will my face be weak after surgery? | Temporary weakness is fairly common; permanent weakness is uncommon when the nerve is preserved |
| Can it come back? | Yes, sometimes after many years, so long-term follow-up matters |
| Will I lose saliva? | Removing one parotid gland rarely causes a dry mouth, because the other glands make up the difference |
11. Questions to ask your care team
- Is my tumour low grade or high grade?
- Was it completely removed with clear margins?
- Was the facial nerve preserved?
- Do I need radiotherapy or a neck dissection?
- How long will my follow-up last?
- What symptoms should make me contact you early?
Resources
- Haller, F. et al. (2019) ‘Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands’, Nature Communications, 10(1), 368.
- Haller, F. et al. (2019b) ‘Nuclear NR4A3 immunostaining is a specific and sensitive novel marker for acinic cell carcinoma of the salivary glands’, American Journal of Surgical Pathology, 43(9), pp. 1264-1272.
- Meiklejohn, K. et al. (2023) ‘Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: role of NOR-1 (NR4A3) immunohistochemistry’, Cytopathology, 34(3), pp. 219-224.
- Patel, N.R. et al. (2014) ‘Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases’, Laryngoscope, 124(1), pp. 172-178.
- Wong, K.S., Mariño-Enriquez, A. and Hornick, J.L. (2021) ‘NR4A3 immunohistochemistry reliably discriminates acinic cell carcinoma from mimics’, Head and Neck Pathology, 15(2), pp. 425-432.
- Yibulayin, F. et al. (2020) ‘Head & neck acinar cell carcinoma: a population-based study using the SEER registry’, BMC Cancer, 20(1), 631.
- Zhu, L. et al. (2024) ‘PON3::LCN1 and HTN3::MSANTD3 gene fusions with NR4A3/NR4A2 expression in salivary acinic cell carcinoma’, American Journal of Surgical Pathology, 48(6), pp. 681-690.
- National Cancer Institute (2026) Salivary Gland Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.